Provided by Tiger Fintech (Singapore) Pte. Ltd.

PDS Biotechnology Corporation

1.12
+0.01000.90%
Post-market: 1.170.0500+4.46%17:27 EDT
Volume:363.07K
Turnover:398.27K
Market Cap:51.20M
PE:-1.20
High:1.12
Open:1.10
Low:1.06
Close:1.11
52wk High:4.29
52wk Low:0.8505
Shares:45.71M
Float Shares:39.88M
Volume Ratio:1.62
T/O Rate:0.91%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.9371
EPS(LYR):-1.0318
ROE:-119.22%
ROA:-38.06%
PB:2.29
PE(LYR):-1.09

Loading ...

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Mar 24

PDS Biotechnology (PDSB): Among the Penny Stocks With Huge Upside Potential According to Analysts

Insider Monkey
·
Mar 23

Life Science Virtual Investor Forum: Presentations Now Available for Online Viewing

GlobeNewswire
·
Mar 14

PDS Biotechnology Price Target Maintained With a $21.00/Share by HC Wainwright & Co.

Dow Jones
·
Mar 14

Analysts Offer Insights on Healthcare Companies: PDS Biotechnology (PDSB) and Cartesian Therapeutics (RNAC)

TIPRANKS
·
Mar 14

BRIEF-PDS Biotech receives FDA clearance to start clinical study on new treatment for metastatic colorectal cancer

Reuters
·
Mar 13

PDS Biotechnology Receives FDA Clearance for Versamune MUC1 Trial in Colon Cancer

MT Newswires Live
·
Mar 13

PDS Biotechnology Price Target Maintained With a $21.00/Share by HC Wainwright & Co.

Dow Jones
·
Mar 08

PDS Biotechnology initiates VERSATILE-003 Phase 3 trial of Versamune HPV

TIPRANKS
·
Mar 07

PDS Biotech Initiates VERSATILE-003 Phase 3 Clinical Trial Evaluating Versamune® HPV in HPV16-Positive Head and Neck Cancer

GlobeNewswire
·
Mar 07

PDS Biotechnology Launches Registered Direct Offering; Shares Up

MT Newswires Live
·
Feb 28

PDS Biotechnology prices 7.33M shares at $1.50 in registered direct offering

TIPRANKS
·
Feb 27

PDS Biotechnology Price Target Maintained With a $21.00/Share by HC Wainwright & Co.

Dow Jones
·
Feb 25

PDS Biotechnology announces circulating tumor DNA results for Versamune HPV

TIPRANKS
·
Feb 24

PDS Biotech Announces Circulating Tumor DNA Results for Versamune® HPV in IMMUNOCERV Trial Published in Clinical Cancer Research

GlobeNewswire
·
Feb 24

PDS Biotech Reaffirms Guidance for First Quarter Initiation of VERSATILE-003 Phase 3 Clinical Trial in HPV16-Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

GlobeNewswire
·
Feb 05